2 days Ago By ABMN Staff
Wells Fargo & Company MN trimmed its holdings in shares of Medpace Holdings, Inc. ( NASDAQ:MEDP – Free Report ) by 2.2% in the 4th quarter, Holdings Channel.
com reports. The firm owned 32,423 shares of the company’s stock after selling 739 shares during the period. Wells Fargo & Company MN’s holdings in Medpace were worth $10,772,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of MEDP. R Squared Ltd bought a new stake in Medpace in the 4th quarter worth approximately $30,000. SBI Securities Co.
Ltd. bought a new stake in shares of Medpace in the 4th quarter worth about $31,000. Jones Financial Companies Lllp lifted its position in Medpace by 2,750.
0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after buying an additional 110 shares during the last quarter. Lindbrook Capital LLC boosted its position in shares of Medpace by 27.
6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after buying an additional 29 shares during the period. Finally, Assetmark Inc.
boosted its position in Medpace by 20.1% in the 4th quarter. Assetmark Inc.
now owns 173 shares of the company’s stock valued at $57,000 after buying an additional 29 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.
Medpace Stock Performance MEDP opened at $296.50 on Thursday. The firm has a 50 day moving average price of $320.
31 and a 200 day moving average price of $333.83. Medpace Holdings, Inc.
has a 1 year low of $272.00 and a 1 year high of $459.77.
The company has a market cap of $8.96 billion, a PE ratio of 23.48, a price-to-earnings-growth ratio of 3.
81 and a beta of 1.46. Analyst Upgrades and Downgrades A number of equities research analysts recently weighed in on the company.
Robert W. Baird upped their price objective on Medpace from $354.00 to $362.
00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. TD Cowen cut shares of Medpace from a “buy” rating to a “hold” rating and dropped their price target for the company from $370.00 to $328.
00 in a research note on Monday. Leerink Partners began coverage on shares of Medpace in a research report on Monday, March 24th. They set a “market perform” rating and a $330.
00 price target on the stock. Truist Financial cut their target price on Medpace from $347.00 to $333.
00 and set a “hold” rating for the company in a research note on Thursday, April 10th. Finally, Mizuho cut their price target on shares of Medpace from $400.00 to $355.
00 and set an “outperform” rating on the stock in a research note on Wednesday, April 9th. Ten analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $357.
50. Read Our Latest Report on Medpace Medpace Profile ( Free Report ) Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Featured Articles Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. ( NASDAQ:MEDP – Free Report ).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter ..
_0.jpg?itok=yAIF6nFK)
